Status:
RECRUITING
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Lead Sponsor:
Rarecells Diagnostics SAS
Collaborating Sponsors:
Meditrial Europe Ltd.
Meditrial SrL
Conditions:
Lung Cancer
Pulmonary Neoplasm
Eligibility:
All Genders
35-85 years
Brief Summary
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management. This study seeks to demonstrate ...
Detailed Description
Researching for tumor biomarkers in the blood, circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA) can non-invasively detect signs of cancer without risk to the patient. These are ideal ...
Eligibility Criteria
Inclusion
- Male or female aged between 35 and 85 years
- Patient diagnosed with resectable lung cancer (by imaging and/or pathological examination) not yet treated for this cancer.
- Patient capable of giving free, informed, and express consent
- The assessment of successful elected surgery implies, but is not limited to, the following:
- Exclusion of detectable extra thoracic and distant metastases
- Determination of the presence or absence of superior mediastinal lymph node metastases
- Definition of the histologic or cell type, whenever possible
- Evaluation of operative risk
Exclusion
- Patient diagnosed and/or treated previously for lung cancer or another cancer, regardless of duration
- Patient treated with neoadjuvant treatment
- Pregnant women
- Patient presenting psychiatric or neurological disorders preventing them from understanding the research
Key Trial Info
Start Date :
November 13 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06546007
Start Date
November 13 2024
End Date
October 1 2025
Last Update
June 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Università Cattolica del Sacro Cuore Gemelli Hospital
Roma, Italy